Switch to Christian Kollmannsberger's research page...

2007

1. Knox JJ, Hotte SJ, Kollmannsberger C, Winquist E, Fisher B, Eisenhauer EA. Phase II study of Triapine(R) in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161). Invest New Drugs. 25(5):471-7. Epub 2007 Mar 28. (2007).
    [View Abstract - PubMed 17393073]  Request Paper

2. Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt-Wolf IG, Berdel WE, Weissinger F, Schleicher J, Egerer G, Haas A, Schirren R, Beyer J, Bokemeyer C, Rick O. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol. 25(19):2778-84. (2007).
    [View Abstract - PubMed 17602082]  Request Paper

3. Oechsle K, Honecker F, Kollmannsberger C, Rick O, Grunwald V, Mayer F, Hartmann JT, Bokemeyer C. An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors. Anticancer Drugs. 18(3):273-6. (2007).
    [View Abstract - PubMed 17264758]  Request Paper

2006

4. Kollmannsberger C, Honecker F, Bokemeyer C. Treatment of germ cell tumors--update 2006. Ann Oncol. 17 Suppl 10:x31-5. (2006).
    [View Abstract - PubMed 17018745]  Request Paper

5. Kollmannsberger C, Nichols C, Bokemeyer C. Recent advances in management of patients with platinum-refractory testicular germ cell tumors. Cancer. 106(6):1217-26. (2006).
    [View Abstract - PubMed 16463389]  Request Paper

6. Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K, Kanz L, Bokemeyer C. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 17(6):1007-13. Epub 2006 Mar 13. (2006).
    [View Abstract - PubMed 16533873]  Request Paper

7. McArthur HL, Dalal BI, Kollmannsberger C. Intravascular hemolysis as a complication of clostridium perfringens sepsis. J Clin Oncol. 24(15):2387-8. (2006).
    [View Abstract - PubMed 16710038]  Request Paper

8. Michels J, Montemurro T, Murray N, Kollmannsberger C, Nguyen Chi K. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Cancer. 106(5):1041-6. (2006).
    [View Abstract - PubMed 16456811]  Request Paper

2005

9. Al-Tourah AJ, Murray N, Coppin C, Kollmannsberger C, Man A, Chi KN. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia. J Urol. 174(6):2209-13, discussion 2213. (2005).
    [View Abstract - PubMed 16280765]  Request Paper

10. Dalal BI, Kollmannsberger C. Drug-induced haemolysis and methaemoglobinaemia in glucose 6-phosphate dehydrogenase deficiency. Br J Haematol. 129(3):291. (2005).
     [View Abstract - PubMed 15842651]  Request Paper

11. Kollmannsberger C, Budach W, Stahl M, Schleucher N, Hehr T, Wilke H, Schleicher J, Vanhoefer U, Jehle EC, Oechsle K, Trarbach T, Boehlke I, Kanz L, Hartmann JT, Bokemeyer C. Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO. Ann Oncol. 16(8):1326-33. Epub 2005 May 26. (2005).
     [View Abstract - PubMed 15919686]  Request Paper

12. Wierecky J, Kollmannsberger C, Boehlke I, Kuczyk M, Schleicher J, Schleucher N, Metzner B, Kanz L, Hartmann JT, Bokemeyer C. Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer. J Cancer Res Clin Oncol. 131(4):255-60. Epub 2004 Dec 31. (2005).
     [View Abstract - PubMed 15627215]  Request Paper

2004

13. Bokemeyer C, Kollmannsberger C, Stenning S, Hartmann JT, Horwich A, Clemm C, Gerl A, Meisner C, Ruckerl CP, Schmoll HJ, Kanz L, Oliver T. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. Br J Cancer. 91(4):683-7. (2004).
     [View Abstract - PubMed 15266338]  Request Paper

14. Kollmannsberger C, Beyer J, Liersch R, Schoeffski P, Metzner B, Hartmann JT, Rick O, Stengele K, Hohloch K, Spott C, Kanz L, Bokemeyer C. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol. 22(1):108-14. (2004).
     [View Abstract - PubMed 14701772]  Request Paper

15. Kuczyk MA, Bokemeyer C, Kollmannsberger C, Corvin S, Anastasiadis A, Machtens S, Merseburger A, Wegener G, Stenze A, Hartmann JT, Jonas U. Late relapse after treatment for nonseminomatous testicular germ cell tumors according to a single center-based experience. World J Urol. 22(1):55-9. (2004).
     [View Abstract - PubMed 15218878]  Request Paper

16. Pfannenberg AC, Oechsle K, Bokemeyer C, Kollmannsberger C, Dohmen BM, Bares R, Hartmann JT, Vonthein R, Claussen CD. The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management. World J Urol. 22(2):132-9. Epub 2004 Jan 21. (2004).
     [View Abstract - PubMed 14735310]  Request Paper

17. Pfannenberg AC, Oechsle K, Kollmannsberger C, Dohmen BM, Bokemeyer C, Bares R, Vontheim R, Claussen CD. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker] Rofo. 176(1):76-84. (2004).
     [View Abstract - PubMed 14712410]  Request Paper

18. Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fossa SD, Skakkebaek NE, de Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, de Mulder PH, Horwich A, Oliver T, Huddart R, Rosti G, Paz Ares L, Pont O, Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J, Clemm S, Culine S, de Wit M, Derigs HG, Dieckmann KP, Flasshove M, Garcia del Muro X, Gerl A, Germa-Lluch JR, Hartmann M, Heidenreich A, Hoeltl W, Joffe J, Jones W, Kaiser G, Klepp O, Kliesch S, Kisbenedek L, Koehrmann KU, Kuczyk M, Laguna MP, Leiva O, Loy V, Mason MD, Mead GM, Mueller RP, Nicolai N, Oosterhof GO, Pottek T, Rick O, Schmidberger H, Sedlmayer F, Siegert W, Studer U, Tjulandin S, von der Maase H, Walz P, Weinknecht S, Weissbach L, Winter E, Wittekind C. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol. 15(9):1377-99. (2004).
     [View Abstract - PubMed 15319245]  Request Paper

2003

19. Bokemeyer C, Schleucher N, Metzner B, Thomas M, Rick O, Schmoll HJ, Kollmannsberger C, Boehlke I, Kanz L, Hartmann JT. First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial. Br J Cancer. 89(1):29-35. (2003).
     [View Abstract - PubMed 12838296]  Request Paper

20. Kollmannsberger C, Schleucher N, Rick O, Metzner B, Hartmann JT, Schoffski P, Beyer J, Casper J, Sosada M, Schmoll HJ, Bohlke I, Meisner C, Kanz L, Bokemeyer C. Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell support. Eur J Cancer. 39(6):775-82. (2003).
     [View Abstract - PubMed 12651203]  Request Paper

21. Kuczyk M, Munch T, Bokemeyer C, Merseburger A, Wefer A, Kollmannsberger C, Kondoh M, Wegener G, Jonas U, Stenzl A. [Is adrenalectomy an indispensable part of nephrectomy? Results of a multivariate statistical analysis] Urologe A. 42(3):366-73. Epub 2003 Jan 15. (2003).
     [View Abstract - PubMed 12671770]  Request Paper

22. Merseburger AS, Wegener G, Horstmann M, Oelke M, Zumbragel A, Bokemeyer C, Kollmannsberger C, Jonas U, Stenzl A, Kuczyk M. [Impact of tumor size on long-term survival of patients with organ-confined renal cell cancer] Aktuelle Urol. 34(7):469-74. (2003).
     [View Abstract - PubMed 14655083]  Request Paper

23. Ott K, Sendler A, Becker K, Dittler HJ, Helmberger H, Busch R, Kollmannsberger C, Siewert JR, Fink U. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer. 6(3):159-67. (2003).
     [View Abstract - PubMed 14520529]  Request Paper

24. Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schoffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer C. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol. 21(22):4083-91. Epub 2003 Oct 20. (2003).
     [View Abstract - PubMed 14568987]  Request Paper

2002

25. Bokemeyer C, Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Claussen CD, Bares R, Kanz L. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET. Br J Cancer. 86(4):506-11. (2002).
     [View Abstract - PubMed 11870528]  Request Paper

26. Honecker F, Kollmannsberger C, Quietzsch D, Haag C, Schroeder M, Spott C, Hartmann JT, Baronius W, Hempel V, Kanz L, Bokemeyer C. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs. 13(5):497-503. (2002).
     [View Abstract - PubMed 12045461]  Request Paper

27. Kollmannsberger C, Mayer F, Pressler H, Koch S, Kanz L, Oosterhuis JW, Looijenga LH, Bokemeyer C. Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer. Cancer. 95(2):301-8. (2002).
     [View Abstract - PubMed 12124830]  Request Paper

28. Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Bares R, Claussen CD, Kanz L, Bokemeyer C. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer. 94(9):2353-62. (2002).
     [View Abstract - PubMed 12015760]  Request Paper

29. Kollmannsberger C, Rick O, Derigs HG, Schleucher N, Schoffski P, Beyer J, Schoch R, Sayer HG, Gerl A, Kuczyk M, Spott C, Kanz L, Bokemeyer C. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol. 20(8):2031-7. (2002).
     [View Abstract - PubMed 11956262]  Request Paper

30. Kollmannsberger C, Rick O, Klaproth H, Kubin T, Sayer HG, Hentrich M, Welslau M, Mayer F, Kuczyk M, Spott C, Kanz L, Bokemeyer C. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group. Br J Cancer. 87(7):729-32. (2002).
     [View Abstract - PubMed 12232755]  Request Paper

31. Kuczyk M, Machtens S, Bokemeyer C, Kollmannsberger C, Hartmann J, Kondoh M, Merseburger A, Jonas U. Surgical bladder preserving strategies in the treatment of muscle-invasive bladder cancer. World J Urol. 20(3):183-9. Epub 2002 Jul 12. (2002).
     [View Abstract - PubMed 12196902]  Request Paper

32. Kuczyk M, Munch T, Machtens S, Bokemeyer C, Wefer A, Hartmann J, Kollmannsberger C, Kondo M, Jonas U. The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover experience. BJU Int. 89(6):517-22. (2002).
     [View Abstract - PubMed 11942955]  Request Paper

2001

33. Dittmann H, Sokler M, Kollmannsberger C, Dohmen BM, Baumann C, Kopp A, Bares R, Claussen CD, Kanz L, Bokemeyer C. Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Oncol Rep. 8(6):1393-9. (2001).
     [View Abstract - PubMed 11605073]  Request Paper

34. Kuczyk MA, Bokemeyer C, Hartmann J, Schubach J, Walter C, Machtens S, Knuchel R, Kollmannsberger C, Jonas U, Serth J. Predictive value of altered p27Kip1 and p21WAF/Cip1 protein expression for the clinical prognosis of patients with localized prostate cancer. Oncol Rep. 8(6):1401-7. (2001).
     [View Abstract - PubMed 11605074]  Request Paper

35. Machtens S, Serth J, Bokemeyer C, Bathke W, Minssen A, Kollmannsberger C, Hartmann J, Knuchel R, Kondo M, Jonas U, Kuczyk M. Expression of the p53 and Maspin protein in primary prostate cancer: correlation with clinical features. Int J Cancer. 95(5):337-42. (2001).
     [View Abstract - PubMed 11494236]  Request Paper

2000

36. Kollmannsberger C, Bokemeyer C. Therapy-Related Leukemia following High-Dose Chemotherapy: Compensating for the Benefit? Onkologie. 23(5):480-482. (2000).
     [View Abstract - PubMed 11441249]  Request Paper

37. Kollmannsberger C, Gerl A, Schleucher N, Beyer J, Kuczyk M, Rick O, Casper J, Sosada M, Rie C, Kanz L, Bokemeyer C. Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer. Anticancer Drugs. 11(7):535-9. (2000).
     [View Abstract - PubMed 11036955]  Request Paper

38. Kollmannsberger C, Nichols C, Bamberg M, Hartmann JT, Schleucher N, Beyer J, Schofski P, Derigs G, Ruther U, Bohlke I, Schmoll HJ, Kanz L, Bokemeyer C. First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases. Ann Oncol. 11(5):553-9. (2000).
     [View Abstract - PubMed 10907948]  Request Paper

39. Kollmannsberger C, Nichols C, Meisner C, Mayer F, Kanz L, Bokemeyer C. Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling. Ann Oncol. 11(9):1115-20. (2000).
     [View Abstract - PubMed 11061604]  Request Paper

40. Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempel V, Clemens M, Kanz L, Bokemeyer C. A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer. 83(4):458-62. (2000).
     [View Abstract - PubMed 10945491]  Request Paper

1999

41. Bokemeyer C, Kollmannsberger C, Harstrick A, Beyer J, Gerl A, Casper J, Metzner B, Hartmann JT, Schmoll HJ, Kanz L. Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG). Int J Cancer. 83(6):848-51. (1999).
     [View Abstract - PubMed 10597209]  Request Paper

42. Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, Nichols C. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol. 17(11):3450-6. (1999).
     [View Abstract - PubMed 10550141]  Request Paper

43. Hartmann JT, Albrecht C, Schmoll HJ, Kuczyk MA, Kollmannsberger C, Bokemeyer C. Long-term effects on sexual function and fertility after treatment of testicular cancer. Br J Cancer. 80(5-6):801-7. (1999).
     [View Abstract - PubMed 10360658]  Request Paper

44. Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer. 83(6):866-9. (1999).
     [View Abstract - PubMed 10597214]  Request Paper

45. Hartmann JT, Quietzsch D, Daikeler T, Kollmannsberger C, Mayer F, Kanz L, Bokemeyer C. Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer. Anticancer Drugs. 10(8):729-33. (1999).
     [View Abstract - PubMed 10573205]  Request Paper

46. Kollmannsberger C, Brugger W, Hartmann JT, Maurer F, Bohm P, Kanz L, Bokemeyer C. Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma. Anticancer Drugs. 10(5):453-6. (1999).
     [View Abstract - PubMed 10477164]  Request Paper

47. Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C. Therapy-related malignancies following treatment of germ cell cancer. Int J Cancer. 83(6):860-3. (1999).
     [View Abstract - PubMed 10597212]  Request Paper

48. Pereira PL, Schick F, Einsele H, Farnsworth CT, Kollmansberger C, Mattke A, Duda SH, Claussen CD. [MR tomography of the bone marrow changes after high-dosage chemotherapy and autologous peripheral stem-cell transplantation] Rofo. 170(3):251-7. (1999).
     [View Abstract - PubMed 10230433]  Request Paper

1998

49. Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, Kanz L. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 77(8):1355-62. (1998).
     [View Abstract - PubMed 9579846]  Request Paper

50. Hartmann JT, Harstrick A, Daikeler T, Kollmannsberger C, Muller C, Seeber S, Kanz L, Bokemeyer C. Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. Anticancer Drugs. 9(5):427-31. (1998).
     [View Abstract - PubMed 9660540]  Request Paper

51. Kollmannsberger C, Beyer J, Droz JP, Harstrick A, Hartmann JT, Biron P, Flechon A, Schoffski P, Kuczyk M, Schmoll HJ, Kanz L, Bokemeyer C. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol. 16(10):3386-91. (1998).
     [View Abstract - PubMed 9779717]  Request Paper

52. Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol. 124(3-4):207-14. (1998).
     [View Abstract - PubMed 9619748]  Request Paper

53. Kollmannsberger C, Peters HD, Fink U. Chemotherapy in advanced pancreatic adenocarcinoma. Cancer Treat Rev. 24(2):133-56. (1998).
     [View Abstract - PubMed 9728423]  Request Paper

1997

54. Bokemeyer C, Lampe CS, Clemens MR, Hartmann JT, Quietzsch D, Forkmann L, Kollmannsberger C, Kanz L. A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. Anticancer Drugs. 8(4):396-9. (1997).
     [View Abstract - PubMed 9180395]  Request Paper